PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 172 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $242,000 | -90.7% | 7,931 | -76.8% | 0.00% | -100.0% |
| Q1 2022 | $2,604,000 | +1182.8% | 34,201 | +909.2% | 0.01% | – |
| Q4 2021 | $203,000 | +1.5% | 3,389 | -4.4% | 0.00% | -100.0% |
| Q3 2021 | $200,000 | -1.5% | 3,546 | +4.8% | 0.00% | 0.0% |
| Q2 2021 | $203,000 | -14.7% | 3,383 | +0.3% | 0.00% | 0.0% |
| Q1 2021 | $238,000 | +19.0% | 3,374 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $200,000 | -23.1% | 3,374 | -22.9% | 0.00% | 0.0% |
| Q3 2020 | $260,000 | +26.8% | 4,374 | +12.2% | 0.00% | 0.0% |
| Q2 2020 | $205,000 | -13.5% | 3,900 | -29.5% | 0.00% | -50.0% |
| Q4 2018 | $237,000 | -13.5% | 5,535 | -1.2% | 0.00% | 0.0% |
| Q3 2018 | $274,000 | -0.4% | 5,603 | -6.6% | 0.00% | 0.0% |
| Q4 2017 | $275,000 | +21.7% | 6,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $226,000 | +3.2% | 6,000 | +44.7% | 0.00% | +100.0% |
| Q1 2016 | $219,000 | -32.6% | 4,147 | -1.8% | 0.00% | -75.0% |
| Q4 2015 | $325,000 | – | 4,225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,799,916 | $121,768,000 | 8.62% |
| Tamarack Advisers, LP | 625,000 | $27,044,000 | 8.22% |
| NEXTHERA CAPITAL LP | 149,086 | $6,484,000 | 5.40% |
| Spyglass Capital Management LLC | 379,609 | $16,509,000 | 5.22% |
| Gagnon Advisors, LLC | 107,412 | $4,671,000 | 2.67% |
| GAGNON SECURITIES LLC | 278,613 | $12,117,000 | 2.61% |
| Asymmetry Capital Management, L.P. | 84,735 | $3,685,000 | 2.00% |
| Rock Springs Capital Management LP | 1,250,000 | $54,363,000 | 1.97% |
| Lisanti Capital Growth, LLC | 118,620 | $5,159,000 | 1.68% |
| Elk Creek Partners, LLC | 500,069 | $21,748,000 | 1.62% |